Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI 860585
- Development stage
- Phase 1
- Lead developer
- Xynomic Pharmaceuticals
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
BI 860585 is a potent, selective, orally administered small molecule inhibitor targeting both mTORC1 and mTORC2 complexes. It acts as an ATP-competitive inhibitor of the serine/threonine kinase activity of mTOR (mechanistic target of rapamycin), thereby blocking downstream signaling pathways involved in cell growth, proliferation, and survival. The drug was originally developed by Boehringer Ingelheim and later licensed to Xynomic Pharmaceuticals for further development. BI 860585 has been evaluated in phase 1 clinical trials as monotherapy and in combination with exemestane or paclitaxel for advanced solid tumors, including breast cancer and colorectal cancer. The agent demonstrated manageable safety profiles with dose-dependent target inhibition and preliminary evidence of disease stabilization or response in several patients[2][4][5][6][7][8].
- Other names
- XP-105XP105XP 105
02
Targets
Mechanistic target of rapamycin kinase complex 2Mechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on BI 860585.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI 860585.